MGJ-Gene Solutions Group Celebrates a Milestone: CAP Accreditation Ceremony on August 6, 2024

Photo: (Left to right) Mr. Tran Van Khoi, Director of LAQAS; Ms. Warinthorn Thanathananon, CAP International Technical Advisor; and Dr. Lam Tuan Thanh, Head of Laboratory, MGJ-Gene Solutions Group.
Photo: (Left to right) Mr. Tran Van Khoi, Director of LAQAS; Ms. Warinthorn Thanathananon, CAP International Technical Advisor; and Dr. Lam Tuan Thanh, Head of Laboratory, MGJ-Gene Solutions Group.

MGJ-Gene Solutions Group proudly hosted the CAP Accreditation ceremony celebrating our achievement as Vietnam’s first NGS laboratory to be accredited by College of American Pathologists (CAP) on August 6, 2024. This prestigious accreditation highlights our unwavering commitment to setting the highest global standards in genetic testing services.

Photo: Representatives from CAP Southeast Asia, LAQAS, Hanoi Medical University Hospital, and MGJ-Gene Solutions Group together
Photo: Representatives from CAP Southeast Asia, LAQAS, Hanoi Medical University Hospital, and MGJ-Gene Solutions Group together

The ceremony was a significant occasion, attended by several distinguished guests who contributed to the significance of the event. We were honored to welcome Ms. Warinthorn Thanathananon, International Technical Advisor for Southeast Asia, South Asia, and Oceania of CAP, as well as Mr. Tran Van Khoi, Director of LAQAS Company and representative of CAP in Vietnam. We were also delighted to have Associate Professor Dr. Dang Thi Ngoc Dung, Former Head of the Laboratory Department at Hanoi Medical University Hospital, and Head of Laboratories at MGJ-Gene Solutions Group, in attendance.

Photo: Dr. Lam Tuan Thanh, Head of Laboratory, MGJ-Gene Solutions Group, sharing insights.
Photo: Dr. Lam Tuan Thanh, Head of Laboratory, MGJ-Gene Solutions Group, sharing insights.

Their presence highlighted the international recognition of our certification and celebrated our alignment with global standards of excellence in genetic testing.

The Accreditation Ceremony not only marked our accreditation but also reaffirmed our commitment to continuous improvement and quality in the field. We extend our deepest gratitude to our dedicated teams and all the distinguished guests for their support and collaboration. This ceremony not only celebrated our achievement but also set the stage for future advancements and continued leadership in genetic testing.

To gain further insights, including an interview with Dr. Lam Tuan Thanh about the significance of our accreditation, view the video below.

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More